➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
AstraZeneca
Moodys
Boehringer Ingelheim
Harvard Business School

Last Updated: May 6, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SIBUTRAMINE HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Sibutramine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00037752 Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates Completed National Heart, Lung, and Blood Institute (NHLBI) N/A 2002-09-01 The purpose of this study is to determine if sibutramine will decrease post-cessation weight gain and cigarette smoking in overweight and obese smokers who quit smoking.
NCT00037752 Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates Completed University of Tennessee N/A 2002-09-01 The purpose of this study is to determine if sibutramine will decrease post-cessation weight gain and cigarette smoking in overweight and obese smokers who quit smoking.
NCT00044187 The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder Completed Eli Lilly and Company Phase 4 2001-04-01 Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity. In this study, the Anti-obesity Agent is being tested to see if it can treat weight gain that may be associated with taking olanzapine. The purposes of this study are to determine the safety of olanzapine when given in combination with the Anti-obesity Agent and any side effects that might be associated with it and whether weight-gain agent can help treat weight gain that may be associated with taking olanzapine.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sibutramine Hydrochloride

Condition Name

Condition Name for Sibutramine Hydrochloride
Intervention Trials
Obesity 28
Overweight 3
Weight Loss 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Sibutramine Hydrochloride
Intervention Trials
Weight Loss 10
Overweight 8
Obesity 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sibutramine Hydrochloride

Trials by Country

Trials by Country for Sibutramine Hydrochloride
Location Trials
United States 82
Greece 2
Canada 2
United Kingdom 1
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Sibutramine Hydrochloride
Location Trials
Texas 6
New York 6
Florida 6
California 5
Minnesota 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sibutramine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Sibutramine Hydrochloride
Clinical Trial Phase Trials
Phase 4 8
Phase 3 9
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Sibutramine Hydrochloride
Clinical Trial Phase Trials
Completed 25
Terminated 5
Recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sibutramine Hydrochloride

Sponsor Name

Sponsor Name for Sibutramine Hydrochloride
Sponsor Trials
Abbott 7
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 3
Mayo Clinic 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Sibutramine Hydrochloride
Sponsor Trials
Industry 20
Other 19
NIH 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Boehringer Ingelheim
Medtronic
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.